Evaluation of adverse drug reactions of anti-tubercular drugs in the treatment of tuberculosis in tertiary care hospital
Keywords:Tuberculosis, Naranjo scale, WHO-UMC scale
Background: Adverse drug reactions are very common among patients on anti-tubercular treatment. Hence, the current study was done to evaluate the adverse drug reaction (ADR) profile in patients receiving anti-tubercular treatment (ATT).
Methods: A 6 months prospective, cross-sectional observational study was performed in collaboration with Pulmonology Medicine department. WHO-UMC scale and Naranjo scale was used to evaluate the ADRs.
Results: Ninety-two patients receiving ATT presented with 113 adverse drug events (ADE). Males were more affected than females. DOTS category-1 regimen was mostly responsible for ADE. Addition of drugs for the management of ADR events was done.
Conclusions: The study results show more ADRs related to ATT demanding increased collaboration between NTEP 2020 and Pharmacovigilance Programme of India to enhance drug safety in this field.
Central TB Division, Ministry of Health and Family Welfare, Government of India. Training modules (1-4) for programme managers and medical officers. Central TB Division, Ministry of Health and Family Welfare, Government of India. June 2020.
Qayyum S, Ahmed I, Baig S, Rizvi N. Adverse events in the treatment of multi-drug resistant tuberculosis. ERS. 2011;4402.
Kurniawati F, Sulaiman SAS, Gillani SW. Adverse Drug Reactions of Primary Antituberculosis Drugs Among Tuberculosis Patients treated in Chest Clinic. Int J Pharm Life Sci. 2012;3(1):13312-8.
Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis. 2005;9(3):248-57.
Breen RAM, Miller RF, Gorsuch T, Smith CJ. Adverse events and treatment interruption in tuberculosis patients with and without HIV coinfection. Thorax. 2006;61:791-4.
Edwards IR, Arsonson JK. Adverse drug reactions: Definitions, diagnosis and management. Lancet. 2000;356:1255-59.
Meyboom RHB, Royer RJ. Causality Classification in Pharmacovigilance Centres in the European Community. Pharmacoepidemiology Drug Safety. 1992;1:87-97.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
Ramanath KV, Ramesh S. A Study on Assessment of Adverse Drug Reaction in Tuberculosis Patients. AM J Pharm Tech Res. 2012;2(2):14-18.
Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Shankar PR. Study of adv drug reaction caused by First line anti-tubercular drug used in directly observed treatment, Short Cause (DOTS) therapy in Western Nepal. Pokhara Pak Med Assoc. 2008;58(10):531-6.
Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. Occurrence of side effects of Anti Tuberculosis Drug in urban Nepalese population under DOTS treatment. Kathmandu J Sci Engineering Technol. 2005;1(1):1-8.
Venkatapraveen A, Rampure MV, Patil N, Hinchageri SS, Lakshmi DP. Assessment of clinical pharmacist intervention to improve compliance and health care outcome of tuberculosis patients. Der Pharmacia Lettre. 2012;4(3):931-37.
Tak DK, Acharya LD, Gowrinath K, Padma RGM, Subish P. Safety evaluation of antitubercular therapy under revised national Tuberculosis Control Progpamme in India. J Clin Diagnostic Res. 2009;3:1395-401.
Ali J. Hepatotoxic effects of tuberculosis therapy. A practical approach to tricky management problem. Postgrad Med. 1996;99:217-31.